@UroMoschini
Account based inItaly
About this account
- Account based in
- Italy
- Connected via
- Italy Android App
Account-level information from X, not a live location or the device used for a specific post.
MD PhD FEBU, Urologist, Milano, Italy. @EAUYAUrology Urothelial Carcinoma Group
Milan, Lombardy
Joined July 2013
- Tweets788
- Following1.3K
- Followers2K
- Likes2.3K
Marco Moschini retweeted
Just released in @NatRevUrol : Integrating clinically actionable biomarkers into bladder cancer care : recommendations from the International Bladder Cancer Group @IBCG_BladderCA
During our deliberations, one theme was clear: biomarkers don't improve care simply because they're "novel or new" They improve care when they're validated, reproducible, and actually change clinical decisions 🧵
@pjhensley11 @jteoh_hk @UrogerliMD @shilpaonc @LauraBukavinaMD @mouwlab @AndreaNecchi @niyatilobo @Agarwal_CaB @LiangChengMD @karima_oualla @drtanws @MaxKates @BrigidaMaiorano @h_alahmadie @TomFlaigMD @AmirHorowitz @WesKassouf @djmcconkey @JanetKukreja @LAUrology_NL @carme_mir1 @UroMoschini @BogdanaSchmidt @VigneshPackiam
Marco Moschini retweeted
New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)
Full text: authors.elsevier.com/a/1mf5C…
@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
Marco Moschini retweeted
🔬✨ Discover the surgical innovations reshaping bladder cancer care on a new Global Perspectives webinar on SIU Academy!
Join top global experts for this informative session on cutting-edge resection techniques, robotic & open radical cystectomy, and real-world strategies to improve outcomes in MIBC.
Watch open access on SIU Academy: bit.ly/3Z3sInF
@fkorkes @jteoh_hk @UroMoschini @SimonemorraMD
Marco Moschini retweeted
What a lovely memento of the #BLADDR25 family. Looking forward to #BLADDR26 in #Amsterdam - come & join us - Dec 2-5 2026! @mirrorsmed @issecam #PROSCA25 #RENALC25
Marco Moschini retweeted
Join us for an interactive seminar on 'Shaping the future: advancing HR-NMIBC management beyond BCG' live from #EMUC25. Register for free here 👉 ecancer.org/EMUC #bladder #urology #Oncology
@LAUrology_NL @UroMoschini @evanguelosx
Marco Moschini retweeted
Fantastic #bladdercancer session at #EMUC2025 with a brilliant discussion and a truly stellar panel. So much is chanhing with new treatments, and urologists need to be ready for what’s coming next.
@Uroweb – at Prague, Czech Republic
Marco Moschini retweeted
🤩Happy to be part of this timely collaborative multicenter review
🧪The role of ICIs in #NMIBC
📰Just published in @Cancers_MDPI @MDPIOpenAccess
👓Read it: t.ly/gYKQp
✍️@evanguelosx @BenjaminPradere @UroMoschini among others
Marco Moschini retweeted
📢 New SOC for MIBC
#ESMO25 Dr. Christof Vulsteke presents KEYNOTE-905:
🚫 No cisplatin? No problem. EV+pembro delivers.
👥 n=344 cis-ineligible MIBC (80% renal impairment, 15% ECOG 2)
🔹 EFS HR 0.40 | OS HR 0.50
🔹 pCR: 57.1% vs 8.6% (ITT, non-op = non-responders)
🔹 No ↑ surgical complications
✅ 1st phase 3 trial showing OS benefit in this population| Unprecedented pCR↑
@urotoday @myESMO
Marco Moschini retweeted
In anticipation of #esmo2025 please find a perfect summary of #bladdercancer trials made by our @UroOnc fellow superstar @hjwang26 .. looking forward to 📊🧑💻 ALBAN, POTOMAC @IBCG_BladderCA @CleClinicUro ..
Marco Moschini retweeted
Explore the current definitions, treatment paradigms, & clinical dilemmas of NMIBC in this new #UROwebinar! The experts will address optimal risk stratification, tx duration, & future therapeutic directions.
Register here 👇
webinars.uroweb.org/EAU/webi…
@LAUrology_NL @UroMoschini
Marco Moschini retweeted
The Urothelial Cancer Update 2025 is officially underway. Esteemed experts are on stage sharing the latest advancements in diagnosis and treatment. What has been the most impactful session for you so far? Let us know in the comments! 👇
@cittasalute_to @unito @UroMolinette – at Turin, Piedmont
Marco Moschini retweeted
Agree with @shilpaonc amazing growth of @IBCG_BladderCA with global mission bringing experts together to develop guidelines based on evidence & consensus! @UrogerliMD @UroMoschini @spsutkaMD @MaxKates @siadaneshmand @shilpaonc @SpiessPhilippe @WesKassouf @AndreaNecchi @UroDocAsh
@UroDocAsh kicking off the @IBCG_BladderCA 3rd annual mtg. Tremendous growth since 2006 now truly a global community of bladderca experts working to improve patient outcomes & address unmet needs keeping the patient at the center of everything.
@WorldBladderCan @UrogerliMD @ #RogerBuckley @jteoh_hk
Marco Moschini retweeted
Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25!
Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided by the patient voice.
Both topics reflect our @IBCG_BladderCA mission: to create real-world solutions that improve outcomes and provide practical tools for patients worldwide; through collaboration, collaboration and ... more collaboration!
@shilpaonc @UrogerliMD @pjhensley11 @BladderCancerUS @WorldBladderCan @AndreaNecchi @PGrivasMDPhD @siadaneshmand @bbmdmsk @MaxKates @VigneshPackiam @LauraBukavinaMD @drtanws @niyatilobo @MarekBabjuk @joanfundi @RobertoContieri @mouwlab @OAlhalabiMD @urotoday @WesKassouf @SimaPorten @UroMoschini @LAUrology_NL @AStenzl @Agarwal_CaB @marigfern @spsutkaMD @jteoh_hk @Heer_Lab @SpiessPhilippe @SWilliams_MD @achoud72 @paolo_gontero @JanetKukreja @BenjaminPradere @GustavoVillold4 @TomFlaigMD @DrByronLee @KKBree @gautiermarcq @LiangChengMD @h_alahmadie @djmcconkey @BogdanaSchmidt @bkonety
Marco Moschini retweeted
Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/43A7qRH
Marco Moschini retweeted
A honor to present the latest updates on urinary #biomarkers in HG NMIBC follow-up at the @Uroweb #uroonco congress. Have you read the DaBlaCa-15 Trial paper published in @EUplatinum? Check that out
Thanks inviting me @foxal72 @UroMoschini and to my opponent @evanguelosx 🙏🏻 – at Seville, Spain
Marco Moschini retweeted
A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol authors.elsevier.com/c/1l7pU…
There is limited evidence on follow-up for IR-NMIBC.
We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.
Marco Moschini retweeted
Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/43A7qRH
Marco Moschini retweeted
Complete vs partial TURBT for muscle-invasive #BladderCancer treatment. @UroLiedberg, @UroMoschini & @BenjaminPradere join @UroDocAsh in a discussion on the extent of transurethral resection of bladder tumor needed in #MIBC. They debate the value of complete resection when considering bladder-sparing approaches, neoadjuvant therapy, and clinical trials. #WatchNow on UroToday > bit.ly/42nD3NM
Marco Moschini retweeted
Review – Bladder Cancer: The Financial Burden of Localized and Metastatic Bladder Cancer by Pietro Scilipoti, @UroMoschini et al
Read the full article here: buff.ly/44pcBYA
#UroSoMe #MedTwitter #EurUrol #BladderCancer
